If you smoke when cancer is found, your team should ask about it, explain why stopping helps, and offer treatment at once: support from an adviser with a stop-smoking medicine or nicotine replacement. Studies link stopping to longer survival, and in one US trial longer support with free medicine helped about one in three quit. NICE says lung cancer surgery should not wait for someone to stop.
NICE NG209 (updated February 2025) gives the general pathway: ask at every opportunity, advise sensitively, offer and (if the person agrees) arrange behavioural support during the visit, prescribe or provide bupropion, cytisinicline, NRT or varenicline to adults before they stop, provide accepted pharmacotherapy immediately, and offer weekly sessions for at least four weeks. It tells people that cytisinicline, combination NRT, varenicline and nicotine-containing e-cigarettes, with behavioural support, are the options more likely to succeed. NICE NG122 adds for lung cancer: advise stopping as soon as the diagnosis is suspected, and do not postpone surgery to allow it. The IASLC position statement (2022) asks that all cancer patients are screened and have access to counselling, pharmacotherapy and follow-up inside multidisciplinary cancer care; NCCN (abstract) sets the same three elements, done concurrently, with retreatment as needed. In a randomised trial in 303 people recently diagnosed with cancer at two United States cancer centres (Park 2020), sustained counselling with free medication gave biochemically confirmed quit rates of 34.5% against 21.5% at six months. Survival evidence is observational: a meta-analysis of 21 lung cancer studies (summary relative risk 0.71) and a cohort of 4526 patients in which benefit was largest when treatment began within six months of diagnosis. The guidelines differ on referral by default: NICE arranges support if the person agrees, while opt-out programmes treat unless the person declines; and NICE names e-cigarettes among the more effective options, which the IASLC statement and the NCCN abstract do not mention. NICE's medicine list reflects United Kingdom licensing; the sources read give no doses or course lengths, which are in each product's own information. The reader's own team's advice comes first.
Why: Treatment cannot be offered to someone whose smoking nobody has asked about, and people who stopped recently may need help to stay stopped.
“At every opportunity, ask people if they smoke or have recently stopped smoking.”
NICE 2025 · [2018]
Why: The IASLC says the harms of continuing to smoke after a cancer diagnosis are under-appreciated. It cites US Surgeon General reports that link continued smoking to more toxicity from cancer treatment and higher mortality, and stopping after diagnosis to improved survival.
“All cancer patients should be screened for tobacco use and advised on the harms of tobacco use and the benefits of tobacco cessation.”
International Association for the Study of Lung Cancer 2022 · Position statement (not graded)
Why: NICE asks for advice that is sensitive to the person's preferences and needs, given together with an explanation of how stop-smoking support can help.
“If they smoke, advise them to stop smoking in a way that is sensitive to their preferences and needs, and advise them that stopping smoking in one go is the best approach. Explain how stop-smoking support can help.”
NICE 2025 · [2018]
Why: NICE asks for support to be arranged while the person is still at the clinic or on the ward, and for immediate support at the outpatient site.
“Offer and, if the person agrees, arrange for them to receive behavioural support to stop smoking during either their current outpatient visit or their inpatient stay.”
NICE 2025 · [2013]
Why: NICE sets the timing for each: with bupropion a quit date within the first 2 weeks of treatment, with cytisinicline within the first 5 days, varenicline started 1 to 2 weeks before the quit date, and nicotine replacement ready to start the day before it. This is NICE's list for adults, written to United Kingdom licensing; the person's own team and pharmacist choose the medicine.
“For adults, prescribe or provide bupropion, cytisinicline, NRT or varenicline before they stop smoking, and for:”
NICE 2025 · [2018], cytisinicline [2025]
Why: NICE asks advisers to say which options are more likely to work and which are less likely. It lists bupropion, and short-acting or long-acting nicotine replacement used without the other, as less likely to succeed.
“Advise people (as appropriate for their age) that the following options, when combined with behavioural support, are more likely to result in them successfully stopping smoking:”
NICE 2025 · [2021], cytisinicline [2025]
Why: NICE asks acute and mental health services to provide the medicine immediately once it is accepted, and to send people home from hospital with enough to last at least 1 week or until their next contact with stop-smoking support.
“If stop-smoking pharmacotherapy is accepted, make sure it is provided immediately.”
NICE 2025 · [2013]
Why: The IASLC reports surveys in which 80 to 90% of oncology providers agreed that stopping smoking should be a standard part of cancer care but fewer than half regularly gave help, and says most patients do not receive evidence-based support as a result.
“All patients should have access to evidence-based tobacco cessation assistance consisting of counseling, pharmacotherapy, and follow-up, and access should be routinely incorporated into multidisciplinary cancer care for all cancer patients and their family members.”
International Association for the Study of Lung Cancer 2022 · Position statement (not graded)
Why: NICE says stopping at any time before surgery has no ill effects and that people who stop in the 8 weeks before surgery can benefit significantly. For lung cancer surgery it asks teams to say that smoking raises the risk of lung complications afterwards.
“Encourage people being referred for elective surgery to stop smoking before their surgery. Refer them to local stop-smoking support.”
NICE 2025 · [2018]
Why: NICE's lung cancer guideline asks for both together: advice to stop as soon as lung cancer is suspected, and surgery that is not postponed while the person tries.
“Do not postpone surgery for lung cancer to allow people to stop smoking.”
NICE 2024 · [2011]
Why: NICE sets this for outpatients from the date they stopped and for inpatients from discharge, preferably face to face, with a referral to local stop-smoking support if the person prefers or the hospital cannot provide it.
“Offer weekly sessions, preferably face to face, for at least 4 weeks after the date they stopped smoking.”
NICE 2025 · [2013]
Why: NICE names clozapine, olanzapine, theophylline and warfarin among the medicines affected by smoking or stopping, asks for the dosage to be adjusted as appropriate, and says it might be possible to reduce the dose of some prescribed medicines when a person stops.
“Monitor people's use of prescribed medicines that are affected by smoking (or stopping smoking) for efficacy and adverse effects.”
NICE 2025 · [2013, amended 2021]
Why: The IASLC notes that many patients who smoke at diagnosis continue or relapse during cancer treatment. NICE asks advisers to encourage people who have not met their goal to try again and to discuss which option to use next; the NCCN panel asks for close follow-up with retreatment as needed.
“Record smoking status and all actions, discussions and decisions related to advice, referrals or interventions about stopping smoking.”
NICE 2025 · [2018]
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Ask everyone, advise in a way sensitive to the person, and treat at once with behavioural support combined with a medicine or nicotine replacement, inside the cancer service, with follow-up and treatment again after relapse. NICE NG209 (updated 2025) supplies the detail and the IASLC statement (2022) and the NCCN guideline (version 3.2022, read as its abstract) set the same three elements for all patients with cancer: counselling, pharmacotherapy and follow-up. The trial evidence in cancer patients supports the combination: in a meta-analysis (Scholten 2024) combined interventions raised quitting (odds ratio 1.67) while medicine alone did not (odds ratio 1.11), on evidence the authors rate very low quality, and in a randomised trial of 303 people (Park 2020) sustained counselling with free medication gave 34.5% against 21.5% confirmed abstinence at six months. Two differences between sources are shown rather than resolved. Referral: NICE arranges support if the person agrees and refers "if appropriate"; opt-out programmes, studied in one cancer centre programme and in one randomised trial in a general hospital, offer treatment to everyone who smokes by default and let them decline. E-cigarettes: NICE names nicotine-containing e-cigarettes among the options more likely to succeed and says long-term harms are not known; the IASLC statement and the NCCN abstract speak only of counselling and pharmacotherapy.
NICE 2025 · NICE 2024 · International Association for the Study of Lung Cancer 2022 · National Comprehensive Cancer Network (J Natl Compr Canc Netw; Shields et al.) 2023 · JAMA (Park et al.) 2020 · Journal of Cancer Policy (Scholten et al.) 2024
Where it differs: Everyone recorded as smoking is contacted or offered treatment by default, without first having to say they are willing to quit, and may decline any part of it. NICE instead words its referral as "Offer and, if the person agrees, arrange for them to receive behavioural support".
Evidence: A randomised trial of 1000 adult patients at one United States hospital (Richter 2023, not a cancer population): verified quit rates with opt-out against opt-in care were 22% against 16% at one month and 19% against 18% at six months; use of medication after discharge was 60% against 34%. In one United States cancer centre programme with no comparison group (Wakeman 2026), 3706 patients who smoked were contacted by default, 1089 chose a treatment, 873 were referred or connected to support, and among those who completed follow-up at 180 days 16.2% (53 of 327) reported abstinence. A proposal to test opt-out referral at diagnosis is linked under upgrades.
JAMA Internal Medicine (Richter et al.) 2023 · Journal of Clinical Oncology (Wakeman et al.) 2026 · NICE 2025
Where it differs: NICE includes nicotine-containing e-cigarettes among the options to be accessible to adults who smoke and among those more likely to succeed with behavioural support. The IASLC statement and the NCCN abstract describe counselling and pharmacotherapy and do not mention e-cigarettes.
Evidence: NICE asks advisers to explain that "there is not enough evidence to know whether there are long-term harms from e-cigarette use" and that "use of e-cigarettes is likely to be substantially less harmful than smoking". NICE also notes that at its February 2025 update no nicotine-containing e-cigarette was licensed as a medicine by the MHRA and commercially available in the UK, and that those not licensed as medicines cannot be marketed by the manufacturer for stopping smoking. This is the United Kingdom position; no source read states the position in other countries. No trial of e-cigarettes in people having cancer treatment was read.
NICE 2025 · International Association for the Study of Lung Cancer 2022 · National Comprehensive Cancer Network (J Natl Compr Canc Netw; Shields et al.) 2023
Where it differs: Four weekly telephone counselling sessions followed by four fortnightly and three monthly ones, with a free choice of nicotine replacement, bupropion or varenicline (the medicines approved by the US Food and Drug Administration that the trial offered), rather than four weekly telephone sessions and advice about medication.
Evidence: Park 2020, a randomised trial at two United States cancer centres in 303 people recently diagnosed with one of eight cancers: biochemically confirmed abstinence at six months was 34.5% against 21.5% (odds ratio 1.92, 95% CI 1.13 to 3.27). The authors state that the generalisability of the findings is uncertain.
Where it differs: NICE advises that stopping in one go is the best approach, and for people who do not want to or are not ready, offers a harm-reduction route using licensed nicotine products with a quit date normally within 6 weeks of starting behavioural support where the person is cutting down to stop.
Evidence: NICE NG209 section 1.15 ([2013]; the box of approaches is [2013, amended 2021]). It also asks advisers to tell people who are not prepared to stop that the health benefits of only reducing are unclear. None of the cancer-specific sources read addresses cutting down.
Quitting smoking around a lung cancer diagnosis is linked to longer survival, and in a randomised trial of people newly diagnosed with cancer, longer counselling with free medicine raised the six-month quit rate from about one in five to one in three. In a survey of 762 accredited United States cancer programmes, 17.6 per cent regularly prescribed stop-smoking medicine.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Advise people to stop as soon as lung cancer is suspected, and say why “Advise people to stop smoking as soon as the diagnosis of lung cancer is suspected and tell them why this is important.” | [2011] | NICE 2024 |
| Tell people that smoking raises the risk of lung complications after lung cancer surgery “Inform people that smoking increases the risk of pulmonary complications after lung cancer surgery.” | [2011] | NICE 2024 |
| Behavioural support offered whichever stop-smoking option the person chooses “Offer behavioural support to people who smoke regardless of which option they choose to help them stop smoking, unless they have chosen the Allen Carr Easyway in-person group seminar.” | [2021, amended 2022] | NICE 2025 |
| Immediate support at the outpatient site for people who smoke “Provide immediate support at the outpatient site.” | [2013] | NICE 2025 |
| Nicotine patches removed 24 hours before microvascular reconstructive surgery and surgery using vasopressin injections “Advise people to remove nicotine replacement therapy patches 24 hours before microvascular reconstructive surgery and surgery using vasopressin injections.” | [2013] | NICE 2025 |
| Cytisinicline not offered to people aged 66 and over “Do not offer cytisinicline to people aged 66 and over.” | [2025] | NICE 2025 |
| Three elements for every patient with cancer who smokes, done together: behaviour therapy, pharmacotherapy, and close follow-up with retreatment “(1) evidence-based motivational strategies and behavior therapy (counseling), which can be brief; (2) evidence-based pharmacotherapy; and (3) close follow-up with retreatment as needed.” | NCCN panel recommendation (category of evidence not given in the abstract) | National Comprehensive Cancer Network (J Natl Compr Canc Netw; Shields et al.) 2023 |
| Universal assessment and documentation of tobacco use as a standard of quality cancer care “Progress on both fronts begins with universal assessment and documentation of tobacco use as a standard of quality cancer care regardless of treatment setting” | Policy statement (not graded) | AACR (Clinical Cancer Research; Toll et al.) 2013 |
| Combined behavioural and pharmacological interventions raise quitting in people with cancer (odds ratio 1.67, 95% CI 1.24 to 2.26); medicine alone did not (odds ratio 1.11, 95% CI 0.69 to 1.78) “A combination of pharmacological and behavioural interventions may be the most effective intervention for smoking cessation in patients with cancer.” | Meta-analysis; overall quality rated very low by GRADE criteria | Journal of Cancer Policy (Scholten et al.) 2024 |
| Quitting at or around a lung cancer diagnosis is associated with better overall survival (summary relative risk 0.71, 95% CI 0.64 to 0.80; 21 observational studies) “Quitting smoking at or around diagnosis was significantly associated with improved overall survival (SRR 0.71, 95% CI 0.64-0.80)” | Meta-analysis of observational studies (not graded) | Journal of Thoracic Oncology (Caini et al.) 2022 |
| In 517 people with early-stage non-small cell lung cancer who smoked at diagnosis, five-year overall survival was 60.6% in those who quit and 48.6% in those who continued (two hospitals in Moscow) | Prospective cohort (not graded) | Annals of Internal Medicine (Sheikh et al.) 2021 |
| Survival benefit is largest when tobacco treatment starts within six months of a cancer diagnosis (cohort of 4526 patients) “The results of this prospective cohort study suggest that evidence-based smoking cessation treatment within 6 months following a cancer diagnosis maximizes survival benefit.” | Prospective cohort (not graded) | JAMA Oncology (Cinciripini et al.) 2024 |
Shares Stop-smoking treatment offered to every person who smokes at a cancer diagnosis, as part of cancer care, Smoking cessation in cancer patients.
Shares Nutrition screening and support during cancer treatment, Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.
Shares Surgical site infection prevention: skin preparation, antibiotic timing, warming and wound care, Prehabilitation before cancer surgery.